PARI Pharma has named Stefan Seemann as its new President, effective July 1, 2021. Seeman will take over from Martin Knoch, who is retiring after more than 30 years at PARI Pharma, where he oversaw development of the company’s eFlow nebulizer technology. Seeman, who joined PARI Pharma in 2000 after several years at Boehringer Inhgelheim, was most recently VP for eFlow Development & Operations.
PARI CEO Johann Zimmermann said, “The appointment of Stefan Seemann prioritizes continuity. In Dr. Seemann we have a very experienced team member from our own ranks taking over the helm – exactly what we need to continue steering PARI Pharma’s business units toward a successful future.”
Seemann commented, “PARI Pharma’s mission is to offer patients with rare and severe respiratory diseases innovative nebulizer therapies that can give them relief and which they can always count on. This motivates us to further leverage our ability to innovate and the expertise we have built up over the decades to provide our partners in the pharmaceutical industry with high-quality customized membrane nebulizer systems based on our eFlow Technology to meet specific patient needs. We are also well positioned to reliably ship our products to our pharma partners over the long term thanks to the expanded capacities at our production facilities in two sites near Munich.”
The company said that it is “focusing on improvements to make all its device solutions even more user-friendly to make the therapy as simple and efficient as possible,” including smart device systems.
Read the PARI Pharma press release.
